"Immunocompromised Host" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation.
| Descriptor ID |
D016867
|
| MeSH Number(s) |
G12.470
|
| Concept/Terms |
Immunocompromised Host- Immunocompromised Host
- Host, Immunocompromised
- Hosts, Immunocompromised
- Immunocompromised Hosts
- Immunocompromised Patient
- Immunocompromised Patients
- Patient, Immunocompromised
- Patients, Immunocompromised
- Immunosuppressed Host
- Host, Immunosuppressed
- Hosts, Immunosuppressed
- Immunosuppressed Hosts
|
Below are MeSH descriptors whose meaning is more general than "Immunocompromised Host".
Below are MeSH descriptors whose meaning is more specific than "Immunocompromised Host".
This graph shows the total number of publications written about "Immunocompromised Host" by people in this website by year, and whether "Immunocompromised Host" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 3 | 5 |
| 1997 | 1 | 1 | 2 |
| 1998 | 3 | 1 | 4 |
| 1999 | 1 | 1 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 2 | 3 | 5 |
| 2004 | 2 | 2 | 4 |
| 2005 | 1 | 1 | 2 |
| 2006 | 4 | 4 | 8 |
| 2007 | 2 | 1 | 3 |
| 2008 | 2 | 4 | 6 |
| 2009 | 2 | 6 | 8 |
| 2010 | 2 | 4 | 6 |
| 2011 | 4 | 6 | 10 |
| 2012 | 1 | 5 | 6 |
| 2013 | 5 | 2 | 7 |
| 2014 | 3 | 5 | 8 |
| 2015 | 3 | 4 | 7 |
| 2016 | 3 | 4 | 7 |
| 2017 | 1 | 11 | 12 |
| 2018 | 5 | 3 | 8 |
| 2019 | 7 | 4 | 11 |
| 2020 | 3 | 4 | 7 |
| 2021 | 4 | 10 | 14 |
| 2022 | 0 | 6 | 6 |
| 2023 | 0 | 2 | 2 |
| 2024 | 5 | 2 | 7 |
| 2025 | 1 | 2 | 3 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunocompromised Host" by people in Profiles.
-
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness. Clin Infect Dis. 2026 Jan 16; 81(Supplement_3):i1-i5.
-
Retreatment or prolonged antiviral therapy in severe acute respiratory syndrome Coronavirus-2 infection among immunocompromised patients during 2022-2023: A nationwide claims-based cohort study in Japan. J Infect Chemother. 2025 Nov; 31(11):102830.
-
Intracranial Rhizomucor Pusillus Mucormycosis in an Adolescent Triggering a Stroke Alert: A Case Report and a Systematic Review of Pediatric Cases. J Child Neurol. 2025 Sep; 40(8):678-685.
-
Scrotal Malakoplakia in a Post-Lung Transplant Patient: A Case Report. Int J Surg Pathol. 2025 Sep; 33(6):1495-1498.
-
Pre-existing Immunocompromising Conditions and Outcomes of Acute COVID-19 Patients Admitted for Pediatric Intensive Care. Clin Infect Dis. 2024 08 16; 79(2):395-404.
-
COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled Trials. Clin Infect Dis. 2024 08 16; 79(2):364-374.
-
Chagas disease in the immunocompromised host. Curr Opin Infect Dis. 2024 Oct 01; 37(5):333-341.
-
Effectiveness of the influenza vaccine for preventing laboratory-confirmed influenza infections in outpatient immunocompromised adults, 2017-2018. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2354013.
-
Chagas disease in immunocompromised patients. Clin Microbiol Rev. 2024 Jun 13; 37(2):e0009923.
-
Phenotypic and functional characterization of posoleucel, a multivirus-specific T cell therapy for the treatment and prevention of viral infections in immunocompromised patients. Cytotherapy. 2024 Aug; 26(8):869-877.